Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T Cells

Frontiers in Immunology

Volumn 5, Issue JAN, 2014, Pages

  Bacchetta, Rosa ^a   Lucarelli, Barbarella ^a   Sartirana, Claudia ^a   Gregori, Silvia ^a   Lupo Stanghellini, Maria T ^b   Miqueu, Patrick ^c   Tomiuk, Stefan ^d   Hernandez Fuentes, Maria ^e   Gianolini, Monica E ^a   Greco, Raffaella ^b   Bernardi, Massimo ^b   Zappone, Elisabetta ^b   Rossini, Silvano ^b   Janssen, Uwe ^d   Ambrosi, Alessandro ^b   Salomoni, Monica ^f   Peccatori, Jacopo ^b   Ciceri, Fabio ^b   Roncarolo, Maria Grazia ^a,g  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c TcLand Expression S A ^*  (Italy)

^d MILTENYI BIOTEC GMBH   (Germany)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f MOLMED S P A   (Italy)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Cell therapy; Haploidentical; Hematopoietic stem cell transplantation; IL 10; T regulatory type 1 cells; Tolerance

Indexed keywords

CELL THERAPY AGENT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 10 ANERGIZED T CELL; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CELL THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE FUNCTION TEST; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; MALE; MICROARRAY ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRINCIPAL COMPONENT ANALYSIS; REGULATORY T LYMPHOCYTE; REMISSION; SURVIVAL;

EID: 84895561909     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00016     Document Type: Article

References (51)

1. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med (1998) 339(17):1186-93. doi: 10.1056/NEJM199810223391702.
2. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol (2005) 23(15):3447-54. doi:10.1200/JCO.2005.09.117.
3. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood (2008) 112(9):3574-81. doi:10.1182/blood-2008-02-140095.
4. Lang P, Handgretinger R. Haploidentical SCT in children: an update and future perspectives. Bone Marrow Transplant (2008) 42(Suppl 2):S54-9. doi:10.1038/bmt.2008.285.
5. Cavazzana-Calvo M, Andre-Schmutz I, Dal Cortivo L, Neven B, Hacein-Bey-Abina S, Fischer A. Immune reconstitution after haematopoietic stem cell transplantation: obstacles and anticipated progress. Curr Opin Immunol (2009) 21(5):544-8. doi:10.1016/j.coi.2009.08.001.
6. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood (2010) 115(19):3861-8. doi:10.1182/blood-2009-12-234096.
7. Lewalle P, Triffet A, Delforge A, Crombez P, Selleslag D, De Muynck H, et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant (2003) 31(1):39-44. doi:10.1038/sj.bmt.1703779.
8. Culme-Seymour EJ, Davie NL, Brindley DA, Edwards-Parton S, Mason C. A decade of cell therapy clinical trials (2000-2010). Regen Med (2012) 7(4):455-62. doi:10.2217/rme.12.45.
9. Riddell SR, Jensen MC, June CH. Chimeric antigen receptor-modified T cells: clinical translation in stem cell transplantation and beyond. Biol Blood Marrow Transplant (2013) 19(1 Suppl):S2-5. doi:10.1016/j.bbmt.2012.10.021.
10. Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol (2009) 10(5):489-500. doi:10.1016/S1470-2045(09)70074-9.
11. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 365(18):1673-83. doi:10.1056/NEJMoa1106152.
12. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 365(8):725-33. doi:10.1056/NEJMoa1103849.
13. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood (2011) 117(14):3921-8. doi:10.1182/blood-2010-10-311894.
14. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2011) 117(3):1061-70. doi:10.1182/blood-2010-07-293795.
15. Edinger M, Hoffmann P. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr Opin Immunol (2011) 23(5):679-84. doi:10.1016/j.coi.2011.06.006.
16. Bacchetta R, Bigler M, Touraine JL, Parkman R, Tovo PA, Abrams J, et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med (1994) 179(2):493-502. doi:10.1084/jem.179.2.493.
17. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 389(6652):737-42. doi:10.1038/39614.
18. Battaglia M, Stabilini A, Draghici E, Gregori S, Mocchetti C, Bonifacio E, et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes (2006) 55(1):40-9. doi:10.2337/diabetes.55.01.06.db05-0613.
19. Serafini G, Andreani M, Testi M, Battarra M, Bontadini A, Biral E, et al. Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. Haematologica (2009) 94(10):1415-26. doi:10.3324/haematol.2008.003129.
20. Gagliani N, Jofra T, Stabilini A, Valle A, Atkinson M, Roncarolo MG, et al. Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant. Diabetes (2010) 59(2):433-9. doi:10.2337/db09-1168.
21. Gagliani N, Jofra T, Valle A, Stabilini A, Morsiani C, Gregori S, et al. Transplant tolerance to pancreatic islets is initiated in the graft and sustained in the spleen. Am J Transplant (2013) 13(8):1963-75. doi:10.1111/ajt.12333.
22. Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med (2013) 19(6):739-46. doi:10.1038/nm.3179.
23. Magnani CF, Alberigo G, Bacchetta R, Serafini G, Andreani M, Roncarolo MG, et al. Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. Eur J Immunol (2011) 41(6):1652-62. doi:10.1002/eji.201041120.
24. 4+ T cells. J Exp Med (1996) 184(1):19-29. doi:10.1084/jem.184.1.19.
25. Bacchetta R, Gregori S, Serafini G, Sartirana C, Schulz U, Zino E, et al. Molecular and functional characterization of allogantigen-specific anergic T cells suitable for cell therapy. Haematologica (2010) 95(12):2134-43. doi:10.3324/haematol.2010.025825.
26. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, et al. Differentiation of type 1 T regulatory (Tr1) cells by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood (2010) 116(6):935-44. doi:10.1182/blood-2009-07-234872.
27. Schwartz RH. T cell anergy. Annu Rev Immunol (2003) 21:305-34. doi:10.1146/annurev.immunol.21.120601.141110.
28. 4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol (1999) 163(7):3684-91.
29. Gregori S, Roncarolo MG, Bacchetta R. Methods for in vitro generation of human type 1 regulatory T cells. Methods Mol Biol (2011) 677:31-46. doi:10.1007/978-1-60761-869-0_3.
30. Guihot A, Dupin N, Marcelin AG, Gorin I, Bedin AS, Bossi P, et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis (2006) 194(8):1078-88. doi:10.1086/507648.
31. Zhang W, Caspell R, Karulin AY, Ahmad M, Haicheur N, Abdelsalam A, et al. ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring-even in hands of ELISPOT-inexperienced investigators. J Immunotoxicol (2009) 6(4):227-34. doi:10.3109/15476910903317546.
32. Brouard S, Dupont A, Giral M, Louis S, Lair D, Braudeau C, et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant (2005) 5(2):330-40. doi:10.1111/j.1600-6143.2004.00700.x.
33. Pannetier C, Cochet M, Darche S, Casrouge A, Zoller M, Kourilsky P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci U S A (1993) 90(9):4319-23. doi:10.1073/pnas.90.9.4319.
34. Sebille F, Gagne K, Guillet M, Degauque N, Pallier A, Brouard S, et al. Direct recognition of foreign MHC determinants by naive T cells mobilizes specific Vbeta families without skewing of the complementarity-determining region 3 length distribution. J Immunol (2001) 167(6):3082-8.
35. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res (2002) 30(1):207-10. doi:10.1093/nar/30.1.207.
36. Ernst J, Bar-Joseph Z. STEM: a tool for the analysis of short time series gene expression data. BMC Bioinformatics (2006) 7:191. doi:10.1186/1471-2105-7-191.
37. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques (2003) 34(2):374-8.
38. Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest (2010) 120(6):1848-61. doi:10.1172/JCI39922.
39. 3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res (2009) 69(2):599-608. doi:10.1158/0008-5472.CAN-08-2361.
40. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest (2010) 120(6):1836-47. doi:10.1172/JCI39933.
41. Aversa F, Martelli MF. Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases. Spring Semin Immunopathol (2004) 26(1-2):155-68. doi:10.1007/s00281-004-0161-7.
42. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity (2004) 21(4):589-601. doi:10.1016/j.immuni.2004.09.002.
43. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood (2004) 104(9):2840-8. doi:10.1182/blood-2004-03-0859.
44. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol (2007) 7(8):585-98. doi:10.1038/nri2138.
45. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity (2009) 30(5):656-65. doi:10.1016/j.immuni.2009.04.006.
46. Hutchinson JA, Riquelme P, Sawitzki B, Tomiuk S, Miqueu P, Zuhayra M, et al. Cutting edge: immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol (2011) 187(5):2072-8. doi:10.4049/jimmunol.1100762.
47. Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood (2009) 113(19):4771-9. doi:10.1182/blood-2008-10-183723.
48. Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood (2006) 108(6):1797-808. doi:10.1182/blood-2006-02-001909.
49. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med (1999) 340(22):1704-14. doi:10.1056/NEJM199906033402202.
50. Davies JK, Gribben JG, Brennan LL, Yuk D, Nadler LM, Guinan EC. Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood (2008) 112(6):2232-41. doi:10.1182/blood-2008-03-143636.
51. Desreumaux P, Foussat A, Allez M, Beaugerie L, Hebuterne X, Bouhnik Y, et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology (2012) 143(5):e1-2. doi:10.1053/j.gastro.2012.07.116.